Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain stem cell transplant aims to restore movement after stroke

NCT ID NCT07709845

Not yet recruiting Disease control Sponsor: Clarion Cells, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This phase 2b trial tests whether injecting allogeneic neural stem cells (CC-101) into the brain near a prior stroke lesion can improve motor function in adults with chronic ischemic stroke and lasting movement problems. About 36 participants will receive either stem cells plus short-term anti-rejection medication, stem cells plus placebo, or a sham surgery plus placebo. The study measures changes in motor skills one year after the procedure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
allogeneic neural stem cells CC-101 (f/k/a NR1) injected into the brain near the stroke lesion, plus short-term tacrolimus
What this could lead to
If successful, this could point toward a new treatment that helps people regain motor function years after a stroke.
What could go wrong
This is an early-phase trial with only 36 participants, so results may not apply broadly. Brain surgery carries risks like infection or bleeding, and the stem cells may not improve function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain ischemia cerebral infarction ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC ISCHEMIC STROKE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.